SUPN:NSD-Supernus Pharmaceuticals Inc (USD)

COMMON STOCK | Drug Manufacturers - Specialty & Generic |

Last Closing

USD 31.84

Change

+0.12 (+0.38)%

Market Cap

USD 1.71B

Volume

0.31M

Analyst Target

USD 29.25
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age. It also offers comprise Qelbree, a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, the company's product candidates include SPN-830, a late-stage drug/device combination product candidate for the treatment of off episodes in PD patients; SPN-817, a novel first-in-class selective acetylcholinesterase inhibitor, which is in Phase II clinical trials for the treatment of epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; SPN-443, a preclinical product for the treatment of ADHD/CNS; and SPN-446 for narcolepsy and SPN-448 for the treatment of CNS which is in discovery stage. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Rockville, Maryland.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-18 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
VTRS Viatris Inc

+0.08 (+0.68%)

USD 13.28B
NBIX Neurocrine Biosciences Inc

-2.46 (-2.01%)

USD 12.34B
ITCI Intracellular Th

-0.41 (-0.55%)

USD 7.97B
LNTH Lantheus Holdings Inc

+2.60 (+2.46%)

USD 7.33B
ALKS Alkermes Plc

+0.09 (+0.32%)

USD 4.58B
ALVO Alvotech

+0.06 (+0.54%)

USD 3.32B
HCM HUTCHMED DRC

+0.02 (+0.12%)

USD 2.95B
AMPH Amphastar P

+1.14 (+2.34%)

USD 2.38B
KNSA Kiniksa Pharmaceuticals Ltd

-0.12 (-0.47%)

USD 1.80B
HROW Harrow Health Inc

+1.76 (+4.04%)

USD 1.60B

ETFs Containing SUPN

W311:XETRA HAN-GINS Indxx Healthcare.. 1.21 % 0.00 %

-0.05 (-0.17%)

USD 0.02B
W311:F HAN-GINS Indxx Healthcare.. 1.21 % 0.00 %

-0.01 (-0.17%)

USD 0.02B
WELL:PA HAN-GINS Indxx Healthcare.. 1.21 % 0.00 %

-0.01 (-0.17%)

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 10.02% 67% D+ 69% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 10.02% 66% D+ 67% D+
Trailing 12 Months  
Capital Gain 15.11% 61% D- 65% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 15.11% 61% D- 62% D
Trailing 5 Years  
Capital Gain 8.23% 73% C 56% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 8.23% 71% C- 48% F
Average Annual (5 Year Horizon)  
Capital Gain 8.83% 62% D 65% D
Dividend Return 8.83% 62% D 62% D
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 23.74% 88% B+ 71% C-
Risk Adjusted Return 37.20% 84% B 69% C-
Market Capitalization 1.71B 87% B+ 77% C+

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector